ARA. V. Rybin

A. V. Rybin

*This is an algorithmically generated author record based on publicly available information.

A. V. Rybin has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experience with Netakimab in patients with ankylosing spondylitis and psoriatic arthritis

    by A. V. Rybin, V. Yu. Manokhin, I. P. Afanasyeva, A. S. Gushchin, I. A. Petrovskaya, N. V. Iunonina, А. В. Рыбин, В. Ю. Манохин, И. П. Афанасьева, А. С. Гущин, et al.

    The aim – to evaluate the efficacy and safety of netakimab (NTK) as first-line or subsequent-line biologic therapy in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in real-world clinical practice. Materials and methods . A retrospective analysis was conducted on data from medical records of patients with AS and PsA hospitalized at the Ivanovo Regional Clinical Hospital between January 2021 and October 2025. Diagnoses were verified according to the ASAS (The Assessment of SpondyloArthritis international Society) 2009 criteria and the modified New York criteria (for AS) and CASPAR (Classification Criteria for Psoriatic Arthritis) (for PsA). Patients were divided into two groups: bio-naive, receiving NTK as first-line therapy, and previously treated, receiving NTK as second-line or subsequent therapy after inefficacy or intolerance of other biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). The dynamics of disease activity indices – BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (for AS and axial PsA) and DAPSA (Disease Activity Index for Psoriatic Arthritis) (for PsA), tender joint (TJC) and swollen joint (SJC) count, patient’s global assessment of disease and pain, as well as laboratory markers of inflammation (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)) – were assessed prior to NTK initiation and at 3, 6, and 12 months. Statistical analysis was performed using a linear mixed-effects model. Results . The analysis of medical documentation data included case histories of 22 patients: 15 (68.2%) women and 7 (31.8%) men, aged from 33 to 68 years, with a mean (SD) age of 48.6±10.5 years. 86% of patients had comorbid conditions. The biologically naive group (n=13) consisted of 7 (54%) patients with AS and 6 (46%) patients with PsA. The pretreated group (n=9) comprised 6 (67%) patients with AS and 3 (33%) patients with PsA. By the end of the year of NTK therapy, a reduction in AS and PsA activity was observed in both groups. In the biologically naive group, 7/13 (53.8%; 95% confidence interval (95% CI): 29.1–76.8) achieved low disease activity according to BASDAI, and 5/6 (83.3%; 95% CI: 43.6–97.0) – according to DAPSA. In the pretreated group, 6/9 (66.7%; 95% CI: 35.4–87.9) achieved low disease activity according to BASDAI, and 3/3 (100%; 95% CI: 43.9–100) – according to DAPSA. The mean BASDAI score decreased from baseline 5.91 (5.15; 6.67) to 2.56 (1.76; 3.37) in biologically naive patients and from 5.08 (4.24; 5.92) to 2.41 (1.50; 3.31) in pretreated patients with AS and axial PsA, corresponding to low disease activity. The DAPSA score in patients with PsA decreased from baseline 31.85 (26.23; 37.48) to 8.51 (2.88; 14.14) in biologically naive patients and from 22.98 (14.15; 31.82) to 6.07 (0.00; 14.90) in pretreated patients. A marked reduction in TJC SJC was observed, along with decreased pain scores and patient global assessment of disease activity, and normalization of acute-phase inflammatory markers (ESR and CRP). No statistically significant differences in the dynamics of all evaluated parameters were found between the biologically naive and pretreated patient groups (p>0.05). The drug demonstrated good tolerability: isolated cases of mild to moderate acute respiratory infections were recorded. Conclusion. Netakimab is an effective and safe drug for the treatment of AS and PsA in real-world clinical practice. The clinical effect of the drug is comparable whether administered as first-line biologic therapy or as a switch from other biologics or tsDMARDs due to inefficacy or intolerance of prior treatment. This supports the appropriateness of using NTK as the drug of choice for AS or PsA therapy both biologic-naïve patients and those with prior experience of biologic therapy.

  • Open Access

    Direct interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis

    by P. A. Shesternya, E. M. Aitova, E. N. Alekseev, I. G. Bannikova, E. A. Bogdanova, D. S. Gordeeva, E. O. Dolishnaya, A. Yu. Doroshevskaya, O. B. Ershova, M. V. Zlobin, et al.

    Interleukin (IL)-6 is a key mediator in the pathogenesis of rheumatoid arthritis (RA). Olokizumab (OKZ, Artlegia®, R-Pharm) is a direct IL-6 inhibitor whose efficacy has been demonstrated in randomized controlled trials, post-marketing studies, and real-world practice. However, different dosing regimens of OKZ and their impact on its usage frequency, as well as on doses of glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs), have been insufficiently studied. Objective: to evaluate the efficacy and safety of OKZ in routine clinical practice, with emphasis on the use of different dosing regimens and concomitant use of GCs and NSAIDs in patients with RA. Material and methods. In a multicenter retrospective observational program included patients in whom OKZ therapy was initiated in real-world clinical practice from 01.12.2023 to 30.11.2024 with subsequent 12-month follow-up. A total of 1240 adult patients with active RA meeting the 2010 ACR/EULAR criteria were enrolled. Of these, 80.5% were women; median age was 55 years; median RA duration was 87 months; 86.5% of patients were rheumatoid factor positive, 82.7% were positive for anti-cyclic citrullinated peptide antibodies; a high comorbidity burden was noted. Patients with incomplete DAS28-CRP/CDAI data or follow-up Results and discussion. At baseline, 89.4% of patients had high/moderate RA activity according to DAS28-CRP. OKZ was prescribed once every 4 weeks in 89.8% of cases; in patients with higher laboratory activity, once every 2 weeks in 10.2% (pConclusion. In the vast majority of cases, OKZ is used at a dose of 64 mg once every 4 weeks, providing achievement of therapeutic targets in real-world clinical practice in most patients (by month 12 – in 78.4%). In our observation trial the proportion of patients who require every 2 week administration was insignificant and included no more than 3% over 12 months of therapy. Therapy is accompanied by a significant reduction in the need for GCs and NSAIDs.


  • Open Access

    Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

    by P. A. Shesternya, A. I. Zagrebneva, O. V. Antipova, Yu. V. Arbuzova, I. G. Bannikova, L. V. Belozertseva, E. A. Bogdanova, S. A. Bykova, E. A. Vasilenko, I. B. Vinogradova, et al.

    Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.